These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29319909)

  • 1. Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes.
    Algeelani S; Alkhelb D; Greenblatt DJ
    Biopharm Drug Dispos; 2018 Mar; 39(3):135-142. PubMed ID: 29319909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.
    Mano Y; Usui T; Kamimura H
    Biopharm Drug Dispos; 2006 Jan; 27(1):1-6. PubMed ID: 16278927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
    Francke S; Mamidi RN; Solanki B; Scheers E; Jadwin A; Favis R; Devineni D
    J Clin Pharmacol; 2015 Sep; 55(9):1061-72. PubMed ID: 25827774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes.
    Mano Y; Usui T; Kamimura H
    Biopharm Drug Dispos; 2005 Jan; 26(1):35-9. PubMed ID: 15593333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation.
    Shao H; Lu J; Xu YT; Zhan Y; Chen GM; Zhang HJ
    Pharmacology; 2016; 97(1-2):18-24. PubMed ID: 26569597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats.
    Fujii T; Nakamura K; Furukawa H; Watanabe M; Kuwashima J; Miyazaki H; Kawashima K; Kuzuya T
    Arzneimittelforschung; 1983; 33(11):1535-7. PubMed ID: 6686448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS.
    Joo J; Kim YW; Wu Z; Shin JH; Lee B; Shon JC; Lee EY; Phuc NM; Liu KH
    Biopharm Drug Dispos; 2015 May; 36(4):258-64. PubMed ID: 25522350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes.
    Mano Y; Usui T; Kamimura H
    Eur J Clin Pharmacol; 2007 Feb; 63(2):211-6. PubMed ID: 17200831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.
    Miners JO; Bowalgaha K; Elliot DJ; Baranczewski P; Knights KM
    Drug Metab Dispos; 2011 Apr; 39(4):644-52. PubMed ID: 21245288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes.
    Vietri M; Pietrabissa A; Mosca F; Pacifici GM
    Eur J Clin Pharmacol; 2002 May; 58(2):93-7. PubMed ID: 12012139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver.
    Mano Y; Usui T; Kamimura H
    Pharm Res; 2006 Jul; 23(7):1502-8. PubMed ID: 16783480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans.
    Mano Y; Usui T; Kamimura H
    J Pharm Sci; 2008 Jul; 97(7):2805-10. PubMed ID: 17763456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes.
    Mano Y; Usui T; Kamimura H
    Drug Metab Dispos; 2007 Apr; 35(4):602-6. PubMed ID: 17267620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
    Chen SZ; Pan PP; Wang SH; Luo J; Hu GX; Xu SS; Zhang L; Yu YF
    Pharmacology; 2015; 95(3-4):133-8. PubMed ID: 25823852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea stimulates liver fructose-2,6-bisphosphate formation in proportion to its hypoglycemic action.
    Hatao K; Kaku K; Matsuda M; Tsuchiya M; Kaneko T
    Diabetes Res Clin Pract; 1985 Mar; 1(1):49-53. PubMed ID: 3939113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
    Gaganis P; Miners JO; Knights KM
    Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of berberine on in vitro metabolism of sulfonylureas: A herb-drug interactions study.
    Singh A; Zhao K; Bell C; Shah AJ
    Rapid Commun Mass Spectrom; 2020 Sep; 34 Suppl 4():e8651. PubMed ID: 31721320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation.
    Sten T; Finel M; Ask B; Rane A; Ekström L
    Steroids; 2009 Nov; 74(12):971-7. PubMed ID: 19643121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.